合并二尖瓣狭窄对经导管主动脉瓣置换术患者临床结局的影响
本研究纳入1339例因重度症状性主动脉瓣狭窄接受TAVR的患者,其中971例有完整超声数据,176例(18.1%)合并二尖瓣狭窄。合并MS患者1年心血管死亡和致残性卒中风险显著增高,差异在30天内即出现,主要由风湿性MS驱动。
要点
- TAVR患者中约五分之一合并二尖瓣狭窄,其中风湿性者预后更差。
- 合并MS与1年心血管死亡风险增加约3.6倍、致残性卒中风险增加约3倍独立相关。
- 不良事件差异在术后30天内即显现,提示需早期识别并加强监测。
核心结论
- 因重度症状性主动脉瓣狭窄行TAVR的患者中约18.1%合并二尖瓣狭窄,与1年心血管不良事件风险增加约三倍相关。
- 合并MS患者的心血管死亡和致残性卒中风险增高在术后30天内即出现,且主要由风湿性MS患者驱动。
研究设计与样本
- 回顾性分析2007年8月至2015年12月间1339例接受TAVR的患者,其中971例(72.5%)具备评估MS严重程度和病因的充分超声心动图数据。
- 按合并MS的程度和病因对患者进行分层,比较合并与不合并MS患者的临床结局。
主要发现
- 176例(18.1%)患者合并MS,平均二尖瓣面积为1.9 ± 0.4 cm2;其中退行性110例(62.5%),风湿性66例(37.5%);中/重度MS 28例(2.9%)。
- 合并与不合并MS的患者基线特征相当。
- 1年时合并MS患者心血管死亡36例(21.4%)vs 66例(8.7%),调整后风险比(HRadj)3.64,95%置信区间(CI)2.38-5.56。
- 1年时合并MS患者致残性卒中12例(7.1%)vs 23例(3.0%),HRadj 2.98,95% CI 1.46-6.09。
- 风湿性MS亚组心血管死亡7例(10.6%)vs 24例(3.2%),HRadj 4.80,95% CI 1.98-11.6;致残性卒中4例(6.1%)vs 16例(2.0%),HRadj 4.18,95% CI 1.34-13.0。
临床怎么用
- 对拟行TAVR的重度主动脉瓣狭窄患者,术前应常规评估是否合并二尖瓣狭窄及其病因。
- 合并MS尤其是风湿性MS的患者,术后早期即应加强监测和干预,以降低心血管死亡和致残性卒中风险。
局限性
- 为单中心回顾性分析,仅72.5%的患者具备评估MS的充分超声数据,可能存在选择偏倚。
- 中/重度MS患者仅28例(2.9%),亚组分析效力有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Multivalvular disease is of increasing concern in elderly patients undergoing transcatheter aortic valve replacement (TAVR). The objective of the present analysis was to investigate the impact of concomitant mitral stenosis (MS) on clinical outcomes in patients undergoing TAVR for severe, symptomatic aortic stenosis (AS). METHODS AND RESULTS: Among 1339 patients undergoing TAVR between August 2007 and December 2015, adequate echocardiographic data for the assessment of severity and aetiology of MS was available in 971 (72.5%) patients. Patients were stratified according to degree and aetiology of concomitant MS. Mitral stenosis was documented in 176 (18.1%) TAVR patients (mean mitral valve area 1.9 ± 0.4 cm2) and considered degenerative in 110 (62.5%) and rheumatic in 66 (37.5%) patients, respectively. Mitral stenosis was categorized as moderate/severe in 28 patients (2.9%). Baseline characteristics were comparable between patients with vs. without MS. At 1 year, patients with MS were at increased risk of cardiovascular death [36 (21.4%) vs. 66 (8.7%); adjusted hazard ratio (HRadj) 3.64, 95% confidence interval (CI) 2.38-5.56] and disabling stroke [12 (7.1%) vs. 23 (3.0%); HRadj 2.98, 95% CI 1.46-6.09] as compared to patients without MS. Differences in cardiovascular death and disabling stroke emerged within 30 days of the index procedure and were largely driven by a difference in patients with rheumatic MS [cardiovascular death: 7 (10.6%) vs. 24 (3.2%), HRadj 4.80, 95% CI 1.98-11.6; disabling stroke: 4 (6.1%) vs. 16 (2.0%), HRadj 4.18, 95% CI 1.34-13.0]. CONCLUSION: Concomitant MS was documented in approximately one-fifth of patients undergoing TAVR for severe, symptomatic AS and associated with a three-fold increased risk of cardiovascular adverse events at 1 year. The difference emerged early and was largely driven by patients with rheumatic MS.
引用
- Asami M, Windecker S, Praz F, et al. Transcatheter aortic valve replacement in patients with concomitant mitral stenosis. Eur Heart J. 2019. PMID: 30596992. doi:10.1093/eurheartj/ehy834
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。